Deal News
InMed Closes Mentari Merger After $490 Million Raise, Ticker MTRI
InMed Pharmaceuticals closed its merger with migraine drug developer Mentari Therapeutics, backed by about $490 million in financing. Shares trade as MTRI from Nov. 9.
Mergers, acquisitions and startup deals, and what they mean.
InMed Pharmaceuticals closed its merger with migraine drug developer Mentari Therapeutics, backed by about $490 million in financing. Shares trade as MTRI from Nov. 9.
We use analytics cookies to see which articles are read. No ads cookies. Privacy policy